Anivive Lifesciences Completes Pivotal Field Study of Laverdia-CA1 (Verdinexor Tablets) for Canine Lymphoma
Shots:
- Anivive has reported completion of its pivotal trial of Laverdia-CA1 to treat dogs with lymphoma where, the final study site was closed on Dec 12, 2024
- The trial assessed Laverdia-CA1 vs PBO in dogs (n=150; selected via AniviveTrial platform from >700 applications) in 12 US sites with results expected in coming months
- Additionally, Anivive plans to submit the effectiveness technical section for the US FDA review this summer, with all other major NADA sections approved, & will seek complete approval in Brazil, Australia, UK, & EU post data finalization
Ref: Prnewswire | Image: Anivive
Related News:- Anivive Lifesciences Receives $20M Funding from Leonid Capital Partners to Develop Novel Programs for Pets
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
